XML 42 R26.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Summary of Significant Accounting Policies (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2016
Accounting Policies [Abstract] |
Schedule of Research and Development Expenses and Reimbursements | Information about the Company’s research and development expenses and reimbursements due under collaboration arrangements for the years ended December 31, 2016, 2015 and 2014 is presented as follows:
|  | Years Ended December 31,
|  | 2016 |  | 2015 |  | 2014
Research and development expense, gross |  | $ | 20,706 |  |  | $ | 17,380 |  |  | $ | 8,717 |
Less: Reimbursement of research and development expense |  | 630 |  |  | 940 |  |  | 430 |
Research and development expense, net of reimbursements |  | $ | 20,076 |  |  | $ | 16,440 |  |  | $ | 8,287 |
Summary of Antidilutive Securities Excluded from Computation of Weighted Average Common Stock Outstanding | The following potentially dilutive shares of common stock have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive
| December 31,
| 2016 |  | 2015
Warrants to purchase Series C-1 Preferred | 14,033 |  |  | 14,033 |
Warrants to purchase common stock associated with June 2016 Public Offering | 4,218,750 |  |  | — |
Warrants to purchase common stock associated with Loan Agreement | 122,435 |  |  | — |
Stock options | 1,819,444 |  |  | 1,379,727 |
Schedule of Segment Reporting Information, by Segment | Information about the Company’s revenue, including revenue in continuing operations and discontinued operations, from different geographic regions for the years ended December 31, 2016, 2015, and 2014 is presented as follows:
| Years Ended December 31,
| 2016 |  | 2015 |  | 2014
United States | $ | — |  |  | — | % |  | $ | 6,931 |  |  | 90 | % |  | $ | 16,422 |  |  | 86 | %
Europe | — |  |  | — |  |  | 477 |  |  | 7 | % |  | 1,235 |  |  | 7 | %
Other non-US | 257 |  |  | 100 | % |  | 257 |  |  | 3 | % |  | 1,367 |  |  | 7 | %
Total revenue | 257 |  |  | 100 | % |  | 7,665 |  |  | 100 | % |  | 19,024 |  |  | 100 | %
Less: Revenue from discontinued operations | — |  |  | — |  |  | 7,408 |  |  | 97 | % |  | 17,768 |  |  | 93 | %
Revenue from continuing operations | $ | 257 |  |  | 100 | % |  | $ | 257 |  |  | 3 | % |  | $ | 1,256 |  |  | 7 | %

X
- Definition Schedule of Research and Development Expenses and Reimbursements [Table Text Block] + References No definition available. + Details
Name: | scyx_ScheduleofResearchandDevelopmentExpensesandReimbursementsTableTextBlock
Namespace Prefix: | scyx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph a -URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration